β-Blockers in hypertension: Studies and meta-analyses over the years

Canadian Journal of Cardiology

Volumn 30, Issue 5 S, 2014, Pages

  Larochelle, Pierre ^a   Tobe, Sheldon W ^b   Lacourcière, Yves ^c  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LABETALOL; METOPROLOL; NADOLOL; NEBIVOLOL; OXPRENOLOL; PERINDOPRIL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; TRANDOLAPRIL; VERAPAMIL;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG METABOLISM; ESSENTIAL TREMOR; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RATE; HUMAN; HYDROPHILICITY; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPOPHILICITY; META ANALYSIS; MIGRAINE; REVIEW; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CANADA; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84898871187     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.02.012     Document Type: Review

References (40)

1. Lindholm L.H., Carlberg B., Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
2. Khan N., McAlister F.A. Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis [erratum in 2007;176:976]. CMAJ 2006, 174:1737-1742.
3. Kuyper L.M., Khan N.A. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 2014, 30(5suppl):S47-S53.
4. Poirier L., Tobe S.W. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol 2014, 30(5 suppl):S9-S15.
5. Ismail R., Teh L.K. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. JClin Pharm Ther 2006, 31:99-109.
6. Lefebvre J., Poirier L., Poirier P., Turgeon J., Lacourcière Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 2007, 63:575-582.
7. Sehrt D., Meineke I., Tzvetkov M., Gültepe S., Brockmöller J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 2011, 12:783-795.
8. Lopez-Sendon J., Swedberg K., McMurray J., et al. Expert consensus on beta-adrenergic receptor blockers of European Society of Cardiology. Eur Heart J 2004, 25:1341-1367.
9. Huang H.L., Fox K.A. The impact of beta blockers on mortality in stable angina: a meta analysis. Scott Med J 2012, 57:69-75.
10. Arandomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982, 247:1707-1714.
11. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. NEngl J Med 1981, 304:801-807.
12. Lim S.S., Vos T., Flaxman A.D., et al. Acomparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 308:224-260.
13. Furberg C.D., Psaty B.M. Calcium antagonists: not appropriate as first line antihypertensive agents. Am J Hypertens 1996, 9:122-125.
14. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000, 288:1967-1975.
15. Savarese G., Costanzo P., Cleland J.G., et al. Meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. JAm Coll Cardiol 2013, 61:131-142.
16. Van Vark L.C., Bertrand M., Akkerhuis K.M., et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012, 33:2088-2097.
17. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985, 291:97-104.
18. The IPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertensives (IPPSH). JHypertens 1985, 3:379-392.
19. Dalhöf B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338:1282-1285.
20. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
21. Wilhelmsen L., Berglund G., Elmfeldt D., et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. JHypertens 1987, 5:561-572.
22. Wikstrand J., Warnold I., Olsson G., et al. Primary prevention with metoprolol in patients with hypertension. JAMA 1988, 259:1976-1982.
23. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Primary Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611-616.
24. Wright J.T., Bakris G.L., Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002, 288:2421-2431.
25. Coope J., Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986, 293:1145-1151.
26. The Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992, 304:405-412.
27. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998, 317:713-720.
28. Zanchetti A., Bond M.G., Henning M. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002, 106:2422-2427.
29. Dalhöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
30. Pepine C.J., Handberg E.M., Cooper-DelHoff R.M. Acalcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
31. Black H.R., Elliott W.J., Grandits G. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
32. Dalhöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005, 366:895-906.
33. William B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
34. Messerli F.H., Grossman E., Glodbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly?. JAMA 1998, 279:1903-1907.
35. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
36. Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice?. Lancet 2004, 364:1684-1689.
37. Wiysonge C.S., Bradley H.A., Volmink J., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012, 11:CD002003.
38. Turnbull F., Neal B., et al. Effects of different regimens on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008, 336:1121-1123. Blood Pressure Lowering Treatment Trialists' Collaboration1.
39. Law M.R., Morris J.K., Wald D.S. Use of blood pressure-lowering drugs in the prevention of cardiovascular disease: meta-analysis randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:1665-1684.
40. Poirier L., Lacourcière Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012, 28:334-340.